Tower Research Capital (TRC)’s TetraLogic Pharmaceuticals Corporation TLOG Stock Holding History

Tower Research Capital (TRC)’s Portfolio TLOG Stock Details TLOG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-6,008	Closed	-$10K	–	5571
2015 Q4	$10K	Buy	+6,008	New	+$10.6K	﹤0.01%	2206
2015 Q1	–	Sell	-1,816	Closed	-$8K	–	5320
2014 Q4	$8K	Buy	1,816 +375	+26%	+$1.68K	﹤0.01%	2394
2014 Q3	$6K	Buy	+1,441	New	+$6.71K	﹤0.01%	3221
2014 Q1	–	Sell	-3,286	Closed	-$29.6K	–	5299
2013 Q4	$31K	Buy	+3,286	New	+$25.6K	0.01%	1872

Other funds holding TLOG

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geneva Advisors Chicago, Illinois $5.81B AUM 23.71% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return

Tower Research Capital (TRC)'s TLOG Position: Q1 2016 in Review

Tower Research Capital (TRC) sold out of TetraLogic Pharmaceuticals Corporation (TLOG) in Q1 2016, closing a stake of 6,008 shares — an estimated $10K sold.

Tower Research Capital (TRC) first reported a position in TLOG in Q4 2013 and held it in 4 quarters. The position peaked at $31K in Q4 2013. 25 funds tracked by Wall St. Rank hold TLOG as of Q1 2016.

Tower Research Capital (TRC) reported no remaining TetraLogic Pharmaceuticals Corporation position as of Q1 2016 after selling out during the quarter.
Tower Research Capital (TRC) sold 6,008 TetraLogic Pharmaceuticals Corporation shares in Q1 2016, an estimated $10K.
Tower Research Capital (TRC) first reported a position in TetraLogic Pharmaceuticals Corporation in Q4 2013 and held it in 4 quarters.
Tower Research Capital (TRC)'s TetraLogic Pharmaceuticals Corporation position peaked at $31K in Q4 2013.
25 funds tracked by Wall St. Rank held TetraLogic Pharmaceuticals Corporation as of Q1 2016.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2016, filed 16 May 2016.